COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc (OTCBB: CBIS) announced the appointment of Mariel Selbovitz, MPH as Vice President of Research Program Development, reflecting the maturing direction of the company with the initiation of the CS-TATI-1 Program and related pandemic drug resistant infectious diseases and co-morbidities research programs to enhance the Company’s scope of expertise on the development of novel phytocannabinoid-based therapeutics, including those for HIV oncology and SAEs of chemotherapy.
